The present invention relates to a pharmaceutical composition comprising omarigliptin or a pharmaceutically acceptable salt thereof and less than 75% by weight of neutral excipients, a process for preparing the pharmaceutical composition and its use in the treatment of type 2 diabetes mellitus.